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Inhibition of Bovine Adenosine Deaminase by AntiHyperglycemic Agents Metformin and Phenformin
Kaitlin Doucette, Neha Amatya, Elizabeth Daniels, Dr. Myoung E. Lee
Department of Chemistry, Winona State University, Winona, Minnesota

ABSTRACT

PURPOSE

Metformin (1,1-dimethylbiguanide) is an anti-hyperglycemic agent that is commonly
used in the oral treatment of Type 2 Diabetes Mellitus. Phenformin
(phenethylbiguanide) is its structural analog. In addition to their anti-hyperglycemic
effects, both metformin and phenformin are known to inhibit proliferation of cancer
cells. Adenosine deaminase is involved in purine nucleoside metabolism and its
activity was elevated in certain cancers such as bladder and renal carcinoma, a
possible cause for the proliferation of these cancer cells. Based on molecular docking
simulations, we have hypothesized that adenosine deaminase could be inhibited by
metformin and phenformin, and that phenformin is a better inhibitor than metformin.
The inhibitory effect of metformin and phenformin on adenosine deaminase from
bovine spleen was studied spectrophotometrically. Non-linear regression analysis
was used to obtain the inhibition constants. Metformin was a competitive inhibitor of
deamination of adenosine with the inhibition constant, KI, of 88 mM. Phenformin
was slightly more effective than metformin as a competitive inhibitor with KI of 10
mM. The KM of adenosine was 31 μM. The inhibition constant values indicate that
neither metformin nor phenformin is a potent inhibitor of adenosine deaminase. It is
unlikely that at the physiological concentration, adenosine deaminase activity would
be greatly affected by either drug.

BACKGROUND
Type 2 Diabetes Mellitus (T2D) is the most common form of diabetes, totaling 90%
to 95% of all cases of diabetes. It is characterized by high blood glucose levels that
result from a decrease in glucose uptake in muscle and adipose tissue, as well as an
increase in hepatic gluconeogenesis1. One of the most common types of oral
medication is metformin, a biguanide anti-hyperglycemic agent. Phenformin was
another biguanide anti-hyperglycemic agent that was removed from most markets in
the 1970s due to high risk of lactic acidosis2.

Figure 1: Metformin
(3-carbamimidoyl-1,1-dimethylbiguanide)

The purpose of this research is to explore the possibility of inhibition of adenosine deaminase (ADA) by metformin
and phenformin.

MATERIALS AND METHODS
In this experiment, the inhibition of ADA obtained from bovine spleen by anti-hyperglycemic agents metformin and
phenformin was studied. The activity of ADA was measured through continuous spectrophotometric rate determination
via UV-vis spectrophotometer at a 265 nm wavelength. Quartz cuvettes containing a 50 mM phosphate buffer at pH
7.4 and adenosine concentrations ranging from 15 µM to 133 µM provided a control group. Metformin was studied at
concentrations of 10 mM, 20 mM, and 40 mM while phenformin was studied at concentrations of 2 mM, 3.3 mM, 4
mM, and 30 mM. All chemicals used in these reactions were purchased from Sigma-Aldrich. The data obtained was
used to calculate ADA activity and was used to create a nonlinear regression graph. Through non-linear regression
analysis of these graphs, calculations of Vmax, Km, and KI were carried out in order to help characterize the type of
inhibition metformin and phenformin present on adenosine deaminase.

RESULTS AND DISCUSSION

In conclusion, it has been determined by nonlinear regression analysis
that ADA activity is competitively inhibited by metformin and
phenformin. However, the competitive inhibition is subtle due to the
fact that the adenosine substrate has a higher binding affinity toward
ADA in a comparison to the inhibitors, metformin and phenformin.

FUTURE WORK
Future work on this research will involve testing AMPD and
determining mode of inhibition of metformin and phenformin on it.
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In this research, ADA is used as a comparative enzyme to extrapolate the effects of
metformin on AMP deaminase. Additionally, adenosine has been found to
accumulate in solid tumors, and has been known to stimulate growth of tumors6. The
possibility of inhibition of ADA by metformin has been explored in previous
research on protein docking simulating software (Figure 3).

It was determined that the Km value is equal to 31 µM. The KI for 20
mM metformin is 88 mM while the KI for 3.3 mM phenformin is 10
mM as seen in Table 1. Since both KI values are larger than the Km, it
can be assumed that the inhibitors reduce the binding affinity of the
enzyme. Phenformin has a smaller KI value than metformin indicating
that it is better at inhibiting ADA activity. The Vmax values are very
similar; therefore, it can be said that the total amount of substrate
being converted into product is similar in all three cases. This suggests
that the inhibitor reduces the affinity of the enzyme for the substrate
but does not decrease the ability of the enzyme to convert substrate
into product if the substrate were to bind to it. Thus, the mode of
inhibition of metformin and phenformin is competitive. The actual
substrate binds tighter to the enzyme than either inhibitor is able to,
implying that a subtle competitive inhibition is taking place.

CONCLUSIONS

Figure 2: Phenformin
(phenethylbiguanide)

There are three proposed mechanisms for the effects of metformin lowering blood
glucose levels in patients with T2D. The first two proposed mechanisms state that
metformin causes inhibition of AMP deaminase (AMPD) and mild, nonspecific
inhibition of mitochondrial electron complex I3 . The inhibition of AMPD and
complex I would have the overall effect of increasing AMP concentration, which
causes the third proposed mechanism: activation of AMP kinase (AMPK)4. The
activation of AMPK causes the stimulation of fatty acid oxidation, inhibition of
cholesterol and triglyceride synthesis, and stimulation of muscle glucose uptake and
modulation of insulin secretion5.
Adenosine deaminase (ADA) is the enzyme that performs a function similar to that
of AMPD in that it converts adenosine into inosine: in the case of AMPD, adenosine
monophosphate into inosine monophosphate (Figure 3).
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Abstract:
Metformin (1,1-dimethylbiguanide) is an anti-hyperglycemic agent that is commonly used in the oral
treatment of Type 2 Diabetes Mellitus. Phenformin (phenethylbiguanide) is its structural analog. In
addition to their anti-hyperglycemic effects, both metformin and phenformin are known to inhibit
proliferation of cancer cells. Adenosine deaminase is involved in purine nucleoside metabolism and its
activity was elevated in certain cancers such as bladder and renal carcinoma, a possible cause for the
proliferation of these cancer cells. Based on molecular docking simulations, we have hypothesized that
adenosine deaminase could be inhibited by metformin and phenformin, and that phenformin is a better
inhibitor than metformin. The inhibitory effect of metformin and phenformin on adenosine deaminase
from bovine spleen was studied spectrophotometrically. Non-linear regression analysis was used to
obtain the inhibition constants. Metformin was a competitive inhibitor of deamination of adenosine
with the inhibition constant, KI, of 88 mM. Phenformin was slightly more effective than metformin as a
competitive inhibitor with KI of 10 mM. The KM of adenosine was 31 μM. The inhibition constant values
indicate that neither metformin nor phenformin is a potent inhibitor of adenosine deaminase. It is
unlikely that at the physiological concentration, adenosine deaminase activity would be greatly affected
by either drug.

Introduction:

Type 2 Diabetes Mellitus (T2D) is the most common form of diabetes, totaling 90% to 95% of all cases of
diabetes. It is characterized by high blood glucose levels that result from a decrease in glucose uptake in
muscle and adipose tissue, as well as an increase in hepatic gluconeogenesis1. One of the most common
types of oral medication is metformin, a biguanide anti-hyperglycemic agent. Phenformin was another
biguanide anti-hyperglycemic agent that was removed from most markets in the 1970s due to high risk
of lactic acidosis2.

Figure 1: Metformin
(3-carbamimidoyl-1,1-dimethylbiguanide)

Figure 2: Phenformin
(phenethylbiguanide)

There are three proposed mechanisms for the effects of metformin lowering blood glucose
levels in patients with T2D. The first two proposed mechanisms state that metformin causes inhibition
of AMP deaminase (AMPD) and mild, nonspecific inhibition of mitochondrial electron complex I3 . The
inhibition of AMPD and complex I would have the overall effect of increasing AMP concentration, which
causes the third proposed mechanism: activation of AMP kinase (AMPK)4. The activation of AMPK
causes the stimulation of fatty acid oxidation, inhibition of cholesterol and triglyceride synthesis, and
stimulation of muscle glucose uptake and modulation of insulin secretion5.
Adenosine deaminase (ADA) is the enzyme that performs a function similar to that of AMPD in that it
converts adenosine into inosine: in the case of AMPD, adenosine monophosphate into inosine
monophosphate (Figure 3).

Figure 3: Irreversible deamination of adenosine.
In this research, ADA is used as a comparative enzyme to extrapolate the effects of metformin
on AMP deaminase. Additionally, adenosine has been found to accumulate in solid tumors, and has
been known to stimulate growth of tumors6. The possibility of inhibition of ADA by metformin has been
explored in previous research on protein docking simulating software (Figure 3).

Figure 4: ADA with both metformin (left image) and adenine (right image) bound at or very near to the
active site of the enzyme. Images obtained from previous Autodock molecular docking simulation.

Results and Discussion:
In this experiment, the inhibition of ADA obtained from bovine spleen by anti-hyperglycemic agents
metformin and phenformin was studied. The activity of ADA was measured through continuous
spectrophotometric rate determination via UV-vis spectrophotometer at a 265 nm wavelength. Quartz
cuvettes containing a 50 mM phosphate buffer at pH 7.4 and adenosine concentrations ranging from 15
µM to 133 µM provided a control group. Metformin was studied at concentrations of 10 mM, 20 mM,
and 40 mM while phenformin was studied at concentrations of 2 mM, 3.3 mM, 4 mM, and 30 mM. All
chemicals used in these reactions were purchased from Sigma-Aldrich. The data obtained was used to
calculate ADA activity and was used to create a nonlinear regression graph. Through non-linear
regression analysis of these graphs, calculations of Vmax, Km, and KI were carried out in order to help
characterize the type of inhibition metformin and phenformin present on adenosine deaminase.

Solutions of adenosine, enzyme, and phosphate buffer were prepared with either metformin or
phenformin, or neither, as a control group. The solutions were made in quartz cuvettes consisting of a
50 mM phosphate buffer at pH 7.4 and adenosine concentrations ranging from 15 µM to 133 µM. The
solutions of enzyme solution containing metformin and phenformin were analyzed
spectrophotometrically at 265 nm, and the activity of the adenosine deaminase was calculated and used
to create a nonlinear regression graph for each.

Figure 5: Nonlinear regression plot of 20 mM metformin

Figure 6: Nonlinear regression plot for 3.3 mM phenformin
The nonlinear regression plots were then used to calculate the Vmax, KM and KI of the enzyme activity.
These calculations were then used to determine the type of inhibition taking place by both metformin
and phenformin, as seen in Table 1.
Concentration (mM)
Vmax (µM inosine/min/mL ADA)
KM (µM)
KI (mM)
Mode of Inhibition
Table 1: Nonlinear regression analysis

Metformin
20
28
31
88
Competitive

Phenformin
3.3
28
31
10
Competitive

Based on the data calculated and shown in Table 1, since both KI values are larger than the KM it is
observed that both metformin and phenformin reduce the binding affinity of adenosine deaminase.
Since phenformin’s KI is smaller than that of metformin, this indicates that it is a stronger inhibitor to
adenosine deaminase than metformin. The Vmax values are similar and thus the total amount of
substrate being converted into product is similar in all three cases: with metformin, with phenformin,
and without any inhibitor. Thus it is implied that both inhibitors reduce the affinity of adenosine
deaminase for adenosine, but does not decrease the ability of the enzyme to convert substrate into
product if the substrate were to bind to it. This suggests that the mode of inhibition of metformin and
phenformin is competitive. However, a very subtle inhibition is taking place, as the actual substrate

binds tighter to the enzyme than either inhibitor. High concentrations of inhibitor are required for any
noticeable effect on the enzyme.

Conclusions:
In conclusion, it has been determined by nonlinear regression analysis that ADA activity is competitively
inhibited by metformin and phenformin. However, the competitive inhibition is subtle due to the fact
that the adenosine substrate has a higher binding affinity toward ADA in a comparison to the inhibitors,
metformin and phenformin.

Future Work:
Future work on this research will involve testing AMPD and determining mode of inhibition that
metformin and phenformin have with regards to the enzyme.
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